Product hub: Capsugel® ZephyrTM – dry-powder inhalation capsule portfolio
Given patient convenience and compatibility with a range of formulations and doses, capsule based dry-powder inhalation (DPI) technology is becoming the preferred DPI drug delivery platform for respiratory and systemic applications.
Lonza’s Capsugel® customised capsules, in both gelatin and hypromellose, are optimised to provide superior performance and compatibility between the capsule/device and capsule/formulation.
Related content from this organisation
- EU secures 80 million doses of Moderna COVID-19 vaccine
- Moderna initiates Phase III trial of COVID-19 vaccine candidate
- Accelerated development of first-in-human (FIH) programmes. Lonza’s SimpliFiH® Solutions
- The opportunities for CDMOs in the pharmaceutical industry
- Germany to lead aseptic sampling market in Europe